Home/Filings/4/0001390478-16-000111
4//SEC Filing

Galena Biopharma, Inc. 4

Accession 0001390478-16-000111

$SLSCIK 0001390478operating

Filed

Jun 6, 8:00 PM ET

Accepted

Jun 7, 6:36 PM ET

Size

16.7 KB

Accession

0001390478-16-000111

Insider Transaction Report

Form 4
Period: 2016-06-01
Dunlap Ryan
Principal Accounting Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2016-06-01$1.75/sh+31,250$54,68849,952 total
  • Exercise/Conversion

    Common Stock

    2016-06-01$1.85/sh+65,625$121,406115,577 total
  • Exercise/Conversion

    Common Stock

    2016-06-01$1.71/sh+30,000$51,300145,577 total
  • Sale

    Common Stock

    2016-06-01$2.18/sh126,875$276,58818,702 total
  • Exercise/Conversion

    Stock Option

    2016-06-0131,25095,625 total
    Exercise: $1.75Common Stock (31,250 underlying)
  • Exercise/Conversion

    Stock Option

    2016-06-0165,62530,000 total
    Exercise: $1.85Common Stock (65,625 underlying)
  • Exercise/Conversion

    Stock Option

    2016-06-0130,0000 total
    Exercise: $1.71Common Stock (30,000 underlying)
Footnotes (5)
  • [F1]The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.16 to $2.22 per share. The reporting person undertakes the provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The trades settled on June 6, 2016.
  • [F2]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/15/15).
  • [F3]This stock option was subject to cancellation on June 29, 2016, which was 90 days after the Reporting person's consulting agreement ended with the Issuer.
  • [F4]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (7/9/12).
  • [F5]The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/29/13).

Issuer

Galena Biopharma, Inc.

CIK 0001390478

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001390478

Filing Metadata

Form type
4
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 6:36 PM ET
Size
16.7 KB